Lymphoblastic Leukemia, Acute, with Lymphomatous Features disease: Malacards - Research Articles, Drugs, Genes, Clinical Trials

MCID: LYM138 MIFTS: 41	Lymphoblastic Leukemia, Acute, with Lymphomatous Features Categories: Immune diseases, Cancer diseases
Genes Variations Tissues Related diseases Publications Pathways Symptoms & Phenotypes Download Expand all tables

Sources

Aliases & Classifications for Lymphoblastic Leukemia, Acute, with Lymphomatous Features

MalaCards integrated aliases for Lymphoblastic Leukemia, Acute, with Lymphomatous Features:

Name: Lymphoblastic Leukemia, Acute, with Lymphomatous Features ⁵⁷ ²⁹ ⁶

Acute Lymphoblastic Leukemia with Lymphomatous Features ⁷³

Leukemia, Acute Lymphoblastic ⁵⁷

Lymphomatous All ⁵⁷

Lall ⁵⁷

Characteristics:

OMIM:

⁵⁷

Inheritance:
acquired specific neoplasm by autosomal recessive mechanism through somatic cell mutation

Classifications:

MalaCards categories:
Global: Cancer diseases
Anatomical: Immune diseases

See all MalaCards categories (disease lists)

External Ids:

OMIM ⁵⁷ 247640

MedGen ⁴² C1855472

SNOMED-CT via HPO ⁶⁹ 115244002 118600007 188676008 more

UMLS ⁷³ C1855472

Sources

Summaries for Lymphoblastic Leukemia, Acute, with Lymphomatous Features

MalaCards based summary : Lymphoblastic Leukemia, Acute, with Lymphomatous Features, also known as acute lymphoblastic leukemia with lymphomatous features, is related to lymphoblastic leukemia and leukemia, acute lymphoblastic. An important gene associated with Lymphoblastic Leukemia, Acute, with Lymphomatous Features is CRLF2 (Cytokine Receptor Like Factor 2), and among its related pathways/superpathways are TGF-Beta Pathway and Akt Signaling. Affiliated tissues include t cells, lymph node and spleen, and related phenotypes are lymphoma and t-cell acute lymphoblastic leukemias

Description from OMIM: 247640

Sources

Related Diseases for Lymphoblastic Leukemia, Acute, with Lymphomatous Features

Diseases related to Lymphoblastic Leukemia, Acute, with Lymphomatous Features via text searches within MalaCards or GeneCards Suite gene sharing:

(show all 28)

#	Related Disease	Score	Top Affiliating Genes
1	lymphoblastic leukemia	26.6	ABL1 CRLF2 IL7R JAK1 JAK2 JAK3
2	leukemia, acute lymphoblastic	12.8
3	leukemia, acute lymphoblastic 3	12.3
4	leukemia, acute lymphoblastic 2	12.3
5	acute lymphocytic leukemia	11.1
6	thrombocythemia 3	10.5	INSL6 JAK2
7	leukemia	10.4
8	lymphoid leukemia	10.4	INSL6 JAK2
9	myeloid and lymphoid neoplasms with eosinophilia and abnormalities of pdgfra, pdgfrb, and fgfr1	10.4	FGFR1 JAK2
10	jak3-deficient severe combined immunodeficiency	10.3	JAK1 JAK3
11	chronic eosinophilic leukemia	10.2	ABL1 FGFR1
12	lactocele	10.0	JAK1 JAK2 JAK3
13	atypical chronic myeloid leukemia	10.0	ABL1 FGFR1 JAK2
14	thrombocytopenia-absent radius syndrome	10.0	FGFR1 JAK2
15	myeloproliferative neoplasm	10.0	ABL1 FGFR1 JAK2
16	t-cell prolymphocytic leukemia	9.9	ABL1 JAK1 JAK3
17	leukemia, chronic myeloid	9.8	ABL1 FGFR1 JAK2
18	systemic mastocytosis	9.7	FGFR1 JAK2
19	hematologic cancer	9.7	ABL1 FGFR1 JAK2
20	leukemia, acute myeloid	9.7
21	acute leukemia	9.7
22	lymphoma	9.7
23	lymphosarcoma	9.7
24	myeloid leukemia	9.7
25	polycythemia vera	9.6	ABL1 JAK1 JAK2 JAK3
26	interleukin-7 receptor alpha deficiency	9.6	IL7R JAK3
27	bone marrow cancer	9.5	ABL1 FGFR1 JAK2 JAK3
28	severe combined immunodeficiency, x-linked	9.4	IL7R JAK3

Graphical network of the top 20 diseases related to Lymphoblastic Leukemia, Acute, with Lymphomatous Features:

Sources

Symptoms & Phenotypes for Lymphoblastic Leukemia, Acute, with Lymphomatous Features

Symptoms via clinical synopsis from OMIM:

⁵⁷

Heme:
acute lymphoblastic leukemia (all)
lymphomatous all (lall)
t-cell all

Lab:
chromosome loss of bands 9p22-p21 by deletion, unbalanced translocation, or loss of entire chromosome
loss of methylthioadenosine phosphorylase in malignant cells during relapse

Misc:
bulky disease of lymph nodes, spleen, and mediastinum

Clinical features from OMIM:

247640

Human phenotypes related to Lymphoblastic Leukemia, Acute, with Lymphomatous Features:

³²

#	Description	HPO Frequency	HPO Source Accession
1	lymphoma ³²		HP:0002665
2	t-cell acute lymphoblastic leukemias ³²		HP:0006727

GenomeRNAi Phenotypes related to Lymphoblastic Leukemia, Acute, with Lymphomatous Features according to GeneCards Suite gene sharing:

²⁶ (show all 36)

#	Description	GenomeRNAi Source Accession	Score	Top Affiliating Genes
1	Decreased viability	GR00221-A-1	10	FGFR1 ABL1
2	Decreased viability	GR00221-A-2	10	FGFR1 JAK1 JAK2 ABL1
3	Decreased viability	GR00221-A-3	10	ABL1
4	Decreased viability	GR00342-S-1	10	ABL1
5	Decreased viability	GR00342-S-2	10	ABL1
6	Decreased viability	GR00342-S-3	10	ABL1
7	Decreased viability	GR00402-S-2	10	FGFR1 JAK1 JAK2 ABL1
8	Increased shRNA abundance (Z-score > 2)	GR00366-A-100	9.87	ABL1 FGFR1
9	Increased shRNA abundance (Z-score > 2)	GR00366-A-105	9.87	JAK3 ABL1
10	Increased shRNA abundance (Z-score > 2)	GR00366-A-11	9.87	JAK3
11	Increased shRNA abundance (Z-score > 2)	GR00366-A-123	9.87	ABL1
12	Increased shRNA abundance (Z-score > 2)	GR00366-A-125	9.87	FGFR1
13	Increased shRNA abundance (Z-score > 2)	GR00366-A-126	9.87	FGFR1
14	Increased shRNA abundance (Z-score > 2)	GR00366-A-143	9.87	IL7R
15	Increased shRNA abundance (Z-score > 2)	GR00366-A-149	9.87	JAK3
16	Increased shRNA abundance (Z-score > 2)	GR00366-A-151	9.87	ABL1
17	Increased shRNA abundance (Z-score > 2)	GR00366-A-156	9.87	IL7R
18	Increased shRNA abundance (Z-score > 2)	GR00366-A-157	9.87	ABL1
19	Increased shRNA abundance (Z-score > 2)	GR00366-A-169	9.87	FGFR1
20	Increased shRNA abundance (Z-score > 2)	GR00366-A-183	9.87	FGFR1
21	Increased shRNA abundance (Z-score > 2)	GR00366-A-189	9.87	IL7R
22	Increased shRNA abundance (Z-score > 2)	GR00366-A-195	9.87	JAK3
23	Increased shRNA abundance (Z-score > 2)	GR00366-A-197	9.87	IL7R
24	Increased shRNA abundance (Z-score > 2)	GR00366-A-2	9.87	IL7R
25	Increased shRNA abundance (Z-score > 2)	GR00366-A-3	9.87	ABL1
26	Increased shRNA abundance (Z-score > 2)	GR00366-A-30	9.87	ABL1
27	Increased shRNA abundance (Z-score > 2)	GR00366-A-43	9.87	IL7R JAK3 ABL1 FGFR1
28	Increased shRNA abundance (Z-score > 2)	GR00366-A-47	9.87	ABL1 FGFR1
29	Increased shRNA abundance (Z-score > 2)	GR00366-A-50	9.87	FGFR1
30	Increased shRNA abundance (Z-score > 2)	GR00366-A-6	9.87	JAK3
31	Increased shRNA abundance (Z-score > 2)	GR00366-A-73	9.87	FGFR1
32	Increased shRNA abundance (Z-score > 2)	GR00366-A-83	9.87	ABL1 FGFR1
33	Increased shRNA abundance (Z-score > 2)	GR00366-A-85	9.87	JAK3 ABL1
34	Increased shRNA abundance (Z-score > 2)	GR00366-A-96	9.87	JAK3
35	Decreased human cytomegalovirus (HCMV) strain AD169 replication	GR00248-A	9.56	ABL1 FGFR1 JAK1 JAK3
36	Decreased viability in HMC1.1 cells	GR00105-A-0	8.96	JAK1 JAK3

MGI Mouse Phenotypes related to Lymphoblastic Leukemia, Acute, with Lymphomatous Features:

⁴⁶

#	Description	MGI Source Accession	Score	Top Affiliating Genes
1	cellular	MP:0005384	9.8	ABL1 CRLF2 FGFR1 IL7R INSL6 JAK2
2	endocrine/exocrine gland	MP:0005379	9.76	ABL1 CRLF2 FGFR1 IL7R INSL6 JAK1
3	hematopoietic system	MP:0005397	9.56	JAK2 JAK3 NT5C2 ABL1 CRLF2 FGFR1
4	immune system	MP:0005387	9.17	ABL1 CRLF2 FGFR1 IL7R JAK1 JAK2

Sources

Drugs & Therapeutics for Lymphoblastic Leukemia, Acute, with Lymphomatous Features

Search Clinical Trials , NIH Clinical Center for Lymphoblastic Leukemia, Acute, with Lymphomatous Features

Sources

Genetic Tests for Lymphoblastic Leukemia, Acute, with Lymphomatous Features

Genetic tests related to Lymphoblastic Leukemia, Acute, with Lymphomatous Features:

#	Genetic test	Affiliating Genes
1	Lymphoblastic Leukemia, Acute, with Lymphomatous Features ²⁹

Sources

Anatomical Context for Lymphoblastic Leukemia, Acute, with Lymphomatous Features

MalaCards organs/tissues related to Lymphoblastic Leukemia, Acute, with Lymphomatous Features:

⁴¹

T Cells, Lymph Node, Spleen, Myeloid

Sources

Publications for Lymphoblastic Leukemia, Acute, with Lymphomatous Features

Articles related to Lymphoblastic Leukemia, Acute, with Lymphomatous Features:

#	Title	Authors	Year
1	Molecular analysis of the CALM/AF10 fusion: identical rearrangements in acute myeloid leukemia, acute lymphoblastic leukemia and malignant lymphoma patients. ( 10637482 )	Bohlander S.K....Dreyling M.H.	2000
2	Expression of MDR1 gene in acute leukemia cells: association with CD7+ acute myeloblastic leukemia/acute lymphoblastic leukemia. ( 7694687 )	Miwa H....Shirakawa S.	1993

Sources

Genes for Lymphoblastic Leukemia, Acute, with Lymphomatous Features

Genes related to Lymphoblastic Leukemia, Acute, with Lymphomatous Features (2 elite genes):

- Elite gene

- Cancer Census gene in COSMIC

#	Symbol	Description	Category	Score	Evidence
1	CRLF2	Cytokine Receptor Like Factor 2	Protein Coding	408.2	Pathogenic ⁶ GeneCards inferred via : Variants (show sections)
2	LALL	Lymphomatous Acute Lymphoblastic Leukemia	Genetic Locus	50	Genetic linkage ⁵⁷
3	ABL1	ABL Proto-Oncogene 1, Non-Receptor Tyrosine Kinase	Protein Coding	43.55	Pathogenic/Likely pathogenic ⁶ GeneCards inferred via : Variants (show sections)
4	FGFR1	Fibroblast Growth Factor Receptor 1	Protein Coding	43.55	Pathogenic/Likely pathogenic ⁶ GeneCards inferred via : Variants (show sections)
5	JAK2	Janus Kinase 2	Protein Coding	18.75	GeneCards inferred via : Variants (show sections)
6	JAK1	Janus Kinase 1	Protein Coding	18.75	GeneCards inferred via : Variants (show sections)
7	INSL6	Insulin Like 6	Protein Coding	18.75	GeneCards inferred via : Variants (show sections)
8	JAK3	Janus Kinase 3	Protein Coding	18.55	GeneCards inferred via : Variants (show sections)
9	NT5C2	5'-Nucleotidase, Cytosolic II	Protein Coding	18.2	GeneCards inferred via : Variants (show sections)
10	IL7R	Interleukin 7 Receptor	Protein Coding	18.2	GeneCards inferred via : Variants (show sections)

Sources

Variations for Lymphoblastic Leukemia, Acute, with Lymphomatous Features

ClinVar genetic disease variations for Lymphoblastic Leukemia, Acute, with Lymphomatous Features:

⁶

(show all 29)

#	Gene	Variation	Type	Significance	SNP ID	Assembly	Location
1	ABL1	NM_007313.2(ABL1): c.1001C> T (p.Thr334Ile)	single nucleotide variant	Pathogenic/Likely pathogenic	rs121913459	GRCh37	Chromosome 9, 133748283: 133748283
2	ABL1	NM_007313.2(ABL1): c.1001C> T (p.Thr334Ile)	single nucleotide variant	Pathogenic/Likely pathogenic	rs121913459	GRCh38	Chromosome 9, 130872896: 130872896
3	ABL1	NM_007313.2(ABL1): c.814T> C (p.Tyr272His)	single nucleotide variant	Pathogenic/Likely pathogenic	rs121913461	GRCh37	Chromosome 9, 133738357: 133738357
4	ABL1	NM_007313.2(ABL1): c.814T> C (p.Tyr272His)	single nucleotide variant	Pathogenic/Likely pathogenic	rs121913461	GRCh38	Chromosome 9, 130862970: 130862970
5	FGFR1	NM_023110.2(FGFR1): c.1966A> G (p.Lys656Glu)	single nucleotide variant	Pathogenic/Likely pathogenic	rs869320694	GRCh37	Chromosome 8, 38272308: 38272308
6	FGFR1	NM_023110.2(FGFR1): c.1966A> G (p.Lys656Glu)	single nucleotide variant	Pathogenic/Likely pathogenic	rs869320694	GRCh38	Chromosome 8, 38414790: 38414790
7	JAK1	NM_002227.3(JAK1): c.1901C> A (p.Ala634Asp)	single nucleotide variant	Likely pathogenic	rs869312953	GRCh37	Chromosome 1, 65312418: 65312418
8	JAK1	NM_002227.3(JAK1): c.1901C> A (p.Ala634Asp)	single nucleotide variant	Likely pathogenic	rs869312953	GRCh38	Chromosome 1, 64846735: 64846735
9	INSL6; JAK2	NM_004972.3(JAK2): c.2047A> G (p.Arg683Gly)	single nucleotide variant	Pathogenic/Likely pathogenic	rs1057519721	GRCh37	Chromosome 9, 5078360: 5078360
10	INSL6; JAK2	NM_004972.3(JAK2): c.2047A> G (p.Arg683Gly)	single nucleotide variant	Pathogenic/Likely pathogenic	rs1057519721	GRCh38	Chromosome 9, 5078360: 5078360
11	INSL6; JAK2	NM_004972.3(JAK2): c.2048G> C (p.Arg683Thr)	single nucleotide variant	Pathogenic	rs1057519722	GRCh37	Chromosome 9, 5078361: 5078361
12	INSL6; JAK2	NM_004972.3(JAK2): c.2048G> C (p.Arg683Thr)	single nucleotide variant	Pathogenic	rs1057519722	GRCh38	Chromosome 9, 5078361: 5078361
13	INSL6; JAK2	NM_004972.3(JAK2): c.2049A> C (p.Arg683Ser)	single nucleotide variant	Pathogenic	rs1057519723	GRCh37	Chromosome 9, 5078362: 5078362
14	INSL6; JAK2	NM_004972.3(JAK2): c.2049A> C (p.Arg683Ser)	single nucleotide variant	Pathogenic	rs1057519723	GRCh38	Chromosome 9, 5078362: 5078362
15	INSL6; JAK2	NM_004972.3(JAK2): c.2049A> T (p.Arg683Ser)	single nucleotide variant	Pathogenic	rs1057519723	GRCh37	Chromosome 9, 5078362: 5078362
16	INSL6; JAK2	NM_004972.3(JAK2): c.2049A> T (p.Arg683Ser)	single nucleotide variant	Pathogenic	rs1057519723	GRCh38	Chromosome 9, 5078362: 5078362
17	CRLF2	NM_022148.3(CRLF2): c.695T> G (p.Phe232Cys)	single nucleotide variant	Pathogenic	rs1057519743	GRCh37	Chromosome X, 1314966: 1314966
18	CRLF2	NM_022148.3(CRLF2): c.695T> G (p.Phe232Cys)	single nucleotide variant	Pathogenic	rs1057519743	GRCh38	Chromosome X, 1196852: 1196852
19	CRLF2	NM_022148.3(CRLF2): c.695T> G (p.Phe232Cys)	single nucleotide variant	Pathogenic	rs1057519743	GRCh38	Chromosome Y, 1196852: 1196852
20	JAK1	NM_002227.3(JAK1): c.1972G> T (p.Val658Phe)	single nucleotide variant	Likely pathogenic	rs1057519753	GRCh37	Chromosome 1, 65312347: 65312347
21	JAK1	NM_002227.3(JAK1): c.1972G> T (p.Val658Phe)	single nucleotide variant	Likely pathogenic	rs1057519753	GRCh38	Chromosome 1, 64846664: 64846664
22	IL7R	NM_002185.4(IL7R): c.553A> T (p.Ser185Cys)	single nucleotide variant	Likely pathogenic	rs1057519759	GRCh37	Chromosome 5, 35873597: 35873597
23	IL7R	NM_002185.4(IL7R): c.553A> T (p.Ser185Cys)	single nucleotide variant	Likely pathogenic	rs1057519759	GRCh38	Chromosome 5, 35873495: 35873495
24	JAK1	NM_002227.3(JAK1): c.1937C> T (p.Ser646Phe)	single nucleotide variant	Likely pathogenic	rs151047872	GRCh37	Chromosome 1, 65312382: 65312382
25	JAK1	NM_002227.3(JAK1): c.1937C> T (p.Ser646Phe)	single nucleotide variant	Likely pathogenic	rs151047872	GRCh38	Chromosome 1, 64846699: 64846699
26	NT5C2	NM_012229.4(NT5C2): c.1075A> C (p.Lys359Gln)	single nucleotide variant	not provided	rs1057519867	GRCh37	Chromosome 10, 104852980: 104852980
27	NT5C2	NM_012229.4(NT5C2): c.1075A> C (p.Lys359Gln)	single nucleotide variant	not provided	rs1057519867	GRCh38	Chromosome 10, 103093223: 103093223
28	FGFR1	NM_023110.2(FGFR1): c.1968G> C (p.Lys656Asn)	single nucleotide variant	Likely pathogenic	rs1057519897	GRCh37	Chromosome 8, 38272306: 38272306
29	FGFR1	NM_023110.2(FGFR1): c.1968G> C (p.Lys656Asn)	single nucleotide variant	Likely pathogenic	rs1057519897	GRCh38	Chromosome 8, 38414788: 38414788

Sources

Expression for Lymphoblastic Leukemia, Acute, with Lymphomatous Features

Search GEO for disease gene expression data for Lymphoblastic Leukemia, Acute, with Lymphomatous Features.

Sources

Pathways for Lymphoblastic Leukemia, Acute, with Lymphomatous Features

Pathways related to Lymphoblastic Leukemia, Acute, with Lymphomatous Features according to GeneCards Suite gene sharing:

(show all 41)

#	Super pathways	Score	Top Affiliating Genes
1	TGF-Beta Pathway ⁶⁴ Show member pathways JAK-STAT Pathway ⁶⁴ JNK Pathway ⁶⁴ MAPK Family Pathway ⁶⁴ Regulation of eIF4 and p70S6K ⁶⁴ SOCS Pathway ⁶⁴	13.31	FGFR1 IL7R JAK1 JAK2 JAK3
2	Akt Signaling ⁶⁴ Show member pathways p38 Signaling ⁶⁴ Tec Kinases Signaling ⁶⁴	13.21	FGFR1 IL7R JAK1 JAK2 JAK3
3	Cytokine Signaling in Immune system ⁶⁶ Show member pathways Signaling by Interleukins ⁶⁶	13.15	FGFR1 IL7R JAK1 JAK2 JAK3
4	PI3K-Akt signaling pathway ³⁷ Show member pathways Human papillomavirus infection ³⁷	12.72	FGFR1 IL7R JAK1 JAK2 JAK3
5	Common Cytokine Receptor Gamma-Chain Family Signaling Pathways ⁶⁵ Show member pathways Adipokines and Insulin Signaling Pathways ⁶⁵ Development Thrombopoietin-regulated cell processes ²² IL-15 Signaling Pathways ⁶⁵ IL-2 Signaling Pathways ⁶⁵ IL-21 Signaling Pathways ⁶⁵ IL-4 Signaling Pathway ¹ IL-4 Signaling Pathways ⁶⁵ IL-7 Signaling Pathways ⁶⁵ IL-9 Pathway ⁶⁴ IL-9 Signaling Pathways ⁶⁵ Immune response IL-4 signaling pathway ²² Immune response IL-9 signaling pathway ²²	12.71	IL7R JAK1 JAK2 JAK3
6	NFAT and Cardiac Hypertrophy ⁶⁴ Show member pathways IGF1R Signaling ⁶⁴ Signaling Involved in Cardiac Hypertrophy ⁶⁴	12.67	FGFR1 JAK1 JAK2 JAK3
7	Glioma ³⁷ Show member pathways EGFR tyrosine kinase inhibitor resistance ³⁷ Endocrine resistance ³⁷ Melanoma ³⁷ Non-small cell lung cancer ³⁷ Signaling Pathways in Glioblastoma ¹	12.55	FGFR1 JAK1 JAK2 JAK3
8	Pathways in cancer ³⁷	12.45	ABL1 FGFR1 IL7R JAK1 JAK2 JAK3
9	Regulation of IFNA signaling ⁶⁶ Show member pathways Cytokine Network ⁶⁴ Immune response IFN alpha/beta signaling pathway ²² Interferon alpha/beta signaling ⁶⁶ Interleukin-19, 20, 22, 24 ⁶⁶ Jak/STAT Signaling Pathway ⁶⁵ Jak-STAT signaling pathway ³⁷	12.32	CRLF2 IL7R JAK1 JAK2 JAK3
10	Th17 cell differentiation ³⁷ Show member pathways Inflammatory bowel disease (IBD) ³⁷ Th1 and Th2 cell differentiation ³⁷	12.28	JAK1 JAK2 JAK3
11	CNTF Signaling ⁶⁴ Show member pathways BDNF Pathway ⁶⁴ FLT3 Signaling ⁶⁴ IL-3 Pathway ⁶⁴ Nur77-Induced AICD in Macrophage ⁶⁴ OSM Pathway ⁶⁴	12.27	JAK1 JAK2 JAK3
12	Development VEGF signaling via VEGFR2 - generic cascades ²² Show member pathways Development VEGF signaling and activation ²² VEGF - VEGF R2 Signaling Pathways ⁶⁵	12.22	JAK1 JAK2 JAK3
13	Toll Comparative Pathway ⁶⁴ Show member pathways IL-1 Pathway ⁶⁴ Immune response MIF in innate immunity response ²² iNOS Signaling ⁶⁴ TLR-TRIF Pathway ⁶⁴	12.09	JAK1 JAK2 JAK3
14	Th1 Differentiation Pathway ⁶⁵ Show member pathways IL27-mediated signaling events ¹ IL-6-type cytokine receptor ligand interactions ⁶⁶ Interleukin-6 family signaling ⁶⁶ Interleukin-6 signaling ⁶⁶ Th17 Differentiation Pathway ⁶⁵	12.08	JAK1 JAK2 JAK3
15	Necroptosis ³⁷ Show member pathways Nanoparticle triggered regulated necrosis ¹	12.04	JAK1 JAK2 JAK3
16	G-protein signaling Ras family GTPases in kinase cascades (scheme) ²² Show member pathways Activation of the AP-1 family of transcription factors ⁶⁶ Immune response Oncostatin M signaling via MAPK in human cells ²² MAPK Cascade ¹ Oncostatin M Signaling Pathway ¹	12.02	JAK1 JAK2 JAK3
17	EGF/EGFR Signaling Pathway ¹	12	ABL1 JAK1 JAK2
18	AKT Signaling Pathway ⁶⁷	11.98	FGFR1 IL7R JAK1
19	G beta-gamma signalling through PI3Kgamma ⁶⁶ Show member pathways G-protein beta-gamma signalling ⁶⁶ GPVI-mediated activation cascade ⁶⁶	11.97	JAK1 JAK2 JAK3
20	Immune response Antigen presentation by MHC class II ²² Show member pathways G-protein signaling N-RAS regulation pathway ²² IL-22 Pathway ⁶⁴ Immune response IL-22 signaling pathway ²²	11.96	JAK1 JAK2 JAK3
21	Tyrosine Kinases / Adaptors ⁴	11.93	ABL1 FGFR1 JAK2
22	IL-2 Signaling Pathway ¹ Show member pathways IL2-mediated signaling events ¹ IL-5 Signaling Pathway ¹	11.87	JAK1 JAK2 JAK3
23	Signaling pathways regulating pluripotency of stem cells ³⁷	11.85	FGFR1 JAK1 JAK2 JAK3
24	Immune response IFN gamma signaling pathway ²² Show member pathways IFN-gamma pathway ¹	11.84	FGFR1 IL7R JAK1 JAK2
25	Interleukin-4 and 13 signaling ⁶⁶	11.77	JAK1 JAK2 JAK3
26	Immune response IL-2 activation and signaling pathway ²² Show member pathways Immune response IL-3 activation and signaling pathway ²²	11.76	JAK1 JAK2 JAK3
27	Cytokine production by Th17 cells in CF (Mouse model) ²² Show member pathways Cytokine production by Th17 cells in CF ²²	11.65	JAK1 JAK2 JAK3
28	IL4-mediated signaling events ¹	11.45	JAK1 JAK2 JAK3
29	Interleukin-11 Signaling Pathway ¹	11.33	JAK1 JAK2
30	RAF-independent MAPK1/3 activation ⁶⁶ Show member pathways MAPK1 (ERK2) activation ⁶⁶ MAPK3 (ERK1) activation ⁶⁶	11.3	JAK1 JAK2
31	IL-7 Signaling Pathway ¹ Show member pathways B-Cell Development ⁶⁴ IL-9 Signaling Pathway ¹	11.3	IL7R JAK1 JAK3
32	Signaling events mediated by TCPTP ¹ Show member pathways MET activates PI3K/AKT signaling ⁶⁶	11.29	JAK1 JAK3
33	Type III Interferon Signaling Pathways ⁶⁵ Show member pathways Type III interferon signaling ¹	11.25	JAK1 JAK2
34	Primary immunodeficiency ³⁷	11.22	IL7R JAK3
35	Type II interferon signaling (IFNG) ¹	11.22	JAK1 JAK2
36	Jak/STAT Signaling Pathway Intracellular Regulation ⁶⁵	11.21	JAK1 JAK2 JAK3
37	Thymic Stromal LymphoPoietin (TSLP) Signaling Pathway ¹	11.13	CRLF2 IL7R JAK1 JAK2
38	Interleukin-7 signaling ⁶⁶	10.99	IL7R JAK1 JAK3
39	Jak-Stat Signaling Pathway ⁶⁷	10.97	ABL1 IL7R JAK1 JAK2 JAK3
40	Th2 Differentiation Pathway ⁶⁵	10.92	CRLF2 JAK1 JAK2 JAK3
41	Immune response_Oncostatin M signaling via JAK-Stat in human cells ²²	10.88	JAK1 JAK2

Sources

GO Terms for Lymphoblastic Leukemia, Acute, with Lymphomatous Features

Cellular components related to Lymphoblastic Leukemia, Acute, with Lymphomatous Features according to GeneCards Suite gene sharing:

#	Name	GO ID	Score	Top Affiliating Genes
1	endomembrane system	GO:0012505	9.13	JAK1 JAK2 JAK3
2	extrinsic component of cytoplasmic side of plasma membrane	GO:0031234	8.92	ABL1 JAK1 JAK2 JAK3

Biological processes related to Lymphoblastic Leukemia, Acute, with Lymphomatous Features according to GeneCards Suite gene sharing:

(show all 34)

#	Name	GO ID	Score	Top Affiliating Genes
1	innate immune response	GO:0045087	9.94	ABL1 JAK1 JAK2 JAK3
2	positive regulation of cell proliferation	GO:0008284	9.93	CRLF2 FGFR1 IL7R JAK2
3	protein phosphorylation	GO:0006468	9.91	ABL1 FGFR1 JAK1 JAK2 JAK3
4	MAPK cascade	GO:0000165	9.83	FGFR1 JAK1 JAK2 JAK3
5	phosphorylation	GO:0016310	9.8	ABL1 FGFR1 JAK1 JAK2 JAK3 NT5C2
6	cell migration	GO:0016477	9.78	FGFR1 JAK1 JAK2 JAK3
7	protein autophosphorylation	GO:0046777	9.73	ABL1 FGFR1 JAK1 JAK2
8	peptidyl-tyrosine phosphorylation	GO:0018108	9.71	ABL1 FGFR1 JAK2 JAK3
9	transmembrane receptor protein tyrosine kinase signaling pathway	GO:0007169	9.67	ABL1 JAK1 JAK2 JAK3
10	interleukin-12-mediated signaling pathway	GO:0035722	9.66	JAK1 JAK2
11	regulation of cell adhesion	GO:0030155	9.66	ABL1 JAK2
12	erythrocyte differentiation	GO:0030218	9.65	JAK2 JAK3
13	B cell proliferation	GO:0042100	9.65	ABL1 IL7R
14	platelet-derived growth factor receptor signaling pathway	GO:0048008	9.65	ABL1 JAK2
15	cytokine-mediated signaling pathway	GO:0019221	9.65	CRLF2 IL7R JAK1 JAK2 JAK3
16	response to antibiotic	GO:0046677	9.64	JAK1 JAK2
17	interleukin-6-mediated signaling pathway	GO:0070102	9.62	JAK1 JAK2
18	JAK-STAT cascade involved in growth hormone signaling pathway	GO:0060397	9.62	JAK2 JAK3
19	negative regulation of cell-cell adhesion	GO:0022408	9.61	ABL1 JAK2
20	regulation of interferon-gamma-mediated signaling pathway	GO:0060334	9.61	JAK1 JAK2
21	interleukin-15-mediated signaling pathway	GO:0035723	9.6	JAK1 JAK3
22	enzyme linked receptor protein signaling pathway	GO:0007167	9.59	JAK2 JAK3
23	interleukin-27-mediated signaling pathway	GO:0070106	9.58	JAK1 JAK2
24	interleukin-2-mediated signaling pathway	GO:0038110	9.58	JAK1 JAK3
25	interleukin-35-mediated signaling pathway	GO:0070757	9.57	JAK1 JAK2
26	regulation of JAK-STAT cascade	GO:0046425	9.56	JAK2 JAK3
27	tyrosine phosphorylation of STAT protein	GO:0007260	9.55	JAK2 JAK3
28	regulation of cell proliferation	GO:0042127	9.55	ABL1 FGFR1 JAK1 JAK2 JAK3
29	interleukin-21-mediated signaling pathway	GO:0038114	9.54	JAK1 JAK3
30	interleukin-9-mediated signaling pathway	GO:0038113	9.49	JAK1 JAK3
31	positive regulation of STAT cascade	GO:1904894	9.46	CRLF2 IL7R
32	peptidyl-tyrosine autophosphorylation	GO:0038083	9.26	ABL1 JAK1 JAK2 JAK3
33	interleukin-7-mediated signaling pathway	GO:0038111	8.92	CRLF2 IL7R JAK1 JAK3
34	cell differentiation	GO:0030154	10.03	ABL1 FGFR1 JAK1 JAK2 JAK3

Molecular functions related to Lymphoblastic Leukemia, Acute, with Lymphomatous Features according to GeneCards Suite gene sharing:

(show all 11)

#	Name	GO ID	Score	Top Affiliating Genes
1	ATP binding	GO:0005524	9.89	ABL1 FGFR1 JAK1 JAK2 JAK3
2	kinase activity	GO:0016301	9.8	ABL1 FGFR1 JAK1 JAK2 JAK3
3	signaling receptor binding	GO:0005102	9.73	ABL1 JAK1 JAK2 JAK3
4	protein kinase activity	GO:0004672	9.72	ABL1 FGFR1 JAK1 JAK2 JAK3
5	nucleotide binding	GO:0000166	9.65	FGFR1 JAK1 JAK2 JAK3 NT5C2
6	cytokine receptor activity	GO:0004896	9.48	CRLF2 IL7R
7	SH2 domain binding	GO:0042169	9.46	ABL1 JAK2
8	Ras guanyl-nucleotide exchange factor activity	GO:0005088	9.46	FGFR1 JAK1 JAK2 JAK3
9	growth hormone receptor binding	GO:0005131	9.37	JAK1 JAK2
10	non-membrane spanning protein tyrosine kinase activity	GO:0004715	9.26	ABL1 JAK1 JAK2 JAK3
11	protein tyrosine kinase activity	GO:0004713	9.02	ABL1 FGFR1 JAK1 JAK2 JAK3

Sources

Sources for Lymphoblastic Leukemia, Acute, with Lymphomatous Features

¹ BioSystems

² BitterDB

³ CDC

⁴ Cell Signaling Technology

⁵ ClinicalTrials

⁶ ClinVar

⁷ CNVD

⁸ Cochrane Library

⁹ Cosmic

¹⁰ dbSNP

¹¹ DGIdb

¹² Disease Ontology

¹³ diseasecard

¹⁴ DiseaseEnhancer

¹⁵ DISEASES

¹⁶ DrugBank

¹⁷ ExPASy

¹⁸ FDA Approved Drugs

¹⁹ FMA

²⁰ GeneAnalytics

²¹ GeneCards

²² GeneGo (Thomson Reuters)

²³ GeneHancer via GeneCards

²⁴ GeneReviews

²⁵ Genetics Home Reference

²⁶ GenomeRNAi

²⁷ GEO DataSets

²⁸ GO

²⁹ GTR

³⁰ HGMD

³¹ HMDB

³² HPO

³³ ICD10

³⁴ ICD10 via Orphanet

³⁵ ICD9CM

³⁶ IUPHAR

³⁷ KEGG

³⁸ LifeMap

³⁹ LncRNADisease

⁴⁰ LOVD

⁴¹ MalaCards

⁴² MedGen

⁴³ MedlinePlus

⁴⁴ MeSH

⁴⁵ MESH via Orphanet

⁴⁶ MGI

⁴⁷ miR2Disease

⁴⁸ NCBI Bookshelf

⁴⁹ NCI

⁵⁰ NCIt

⁵¹ NDF-RT

⁵² NIH Clinical Center

⁵³ NIH Rare Diseases

⁵⁴ NINDS

⁵⁵ Novoseek

⁵⁶ Novus Biologicals

⁵⁷ OMIM

⁵⁸ OMIM via Orphanet

⁵⁹ Orphanet

⁶⁰ PathCards

⁶¹ PharmGKB

⁶² PubMed

⁶³ PubMed Health

⁶⁴ QIAGEN

⁶⁵ R&D Systems

⁶⁶ Reactome

⁶⁷ Sino Biological

⁶⁸ SNOMED-CT

⁶⁹ SNOMED-CT via HPO

⁷⁰ SNOMED-CT via Orphanet

⁷¹ TGDB

⁷² Tocris

⁷³ UMLS

⁷⁴ UMLS via Orphanet

⁷⁵ UniProtKB/Swiss-Prot

⁷⁶ Wikipedia